DIFFERENTIAL EFFECTS BETWEEN MARIMASTAT, A TNF-α CONVERTING ENZYME INHIBITOR, AND ANTI-TNF-α ANTIBODY ON MURINE MODELS FOR SEPSIS AND ARTHRITIS
- 1 March 2002
- journal article
- Published by Elsevier BV in Cytokine
- Vol. 17 (6), 294-300
- https://doi.org/10.1006/cyto.2002.1015
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatmentAnnals Of The Rheumatic Diseases, 1999
- A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signalingEuropean Journal of Immunology, 1997
- Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-αNature, 1997
- A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cellsNature, 1997
- The type I interleukin‐1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF‐transgenic miceEuropean Journal of Immunology, 1995
- Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processingNature, 1994
- Increased levels of circulating intercellular adhesion molecule 1 in the sera of patients with rheumatoid arthritisArthritis & Rheumatism, 1993
- Mice lacking the tumour necrosis factor receptor 1 are resistant to IMF-mediated toxicity but highly susceptible to infection by Listeria monocytogenesNature, 1993
- Two TNF receptorsImmunology Today, 1992
- A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNFCell, 1988